ID   Karpas-1106P
AC   CVCL_1821
SY   Karpas-1106p; KARPAS-1106P; Karpas 1106P; KARPAS 1106P; KARPAS1106P; Karpas1106P; Karpas-1106; Karpas 1106; Karpas1106; K1106
DR   EFO; EFO_0006606
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470811
DR   cancercelllines; CVCL_1821
DR   Cell_Model_Passport; SIDM01011
DR   ChEMBL-Cells; CHEMBL4523588
DR   ChEMBL-Targets; CHEMBL4523591
DR   Cosmic; 1013890
DR   Cosmic; 1278829
DR   Cosmic; 1289975
DR   Cosmic; 2276324
DR   Cosmic; 2297035
DR   Cosmic; 2437271
DR   Cosmic; 2479248
DR   Cosmic-CLP; 1327773
DR   DepMap; ACH-002254
DR   DSMZ; ACC-545
DR   DSMZCellDive; ACC-545
DR   ECACC; 06072607
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1327773
DR   GEO; GSM119503
DR   GEO; GSM157143
DR   GEO; GSM380128
DR   GEO; GSM552445
DR   GEO; GSM1374584
DR   GEO; GSM1374585
DR   GEO; GSM1669973
DR   GEO; GSM1897961
DR   Lonza; 1123
DR   PharmacoDB; KARPAS1106P_727_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1821
DR   PubChem_Cell_line; CVCL_1821
DR   Wikidata; Q54899481
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7849311;
RX   PubMed=7949096;
RX   PubMed=9724100;
RX   PubMed=16960149;
RX   PubMed=19278952;
RX   PubMed=20628145;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~60-100 hours (ECACC=06072607).
CC   HLA typing: A*03:01,24:02; B*35:01,51:01; C*04:01,16:02; DQA1*03:02,05:01; DQB1*03:02,03:02; DRB1*03:17,03:17 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.68%; Native American=0.48%; East Asian, North=0.25%; East Asian, South=1.18%; South Asian=11.86%; European, North=19.43%; European, South=65.12% (PubMed=30894373).
CC   Discontinued: DSMZ; ACC-545; true.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,11
ST   D16S539: 9
ST   D18S51: 21
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 17,23
ST   D3S1358: 15
ST   D5S818: 8,14
ST   D7S820: 9,13
ST   D8S1179: 8,15
ST   FGA: 21,22
ST   Penta D: 8,11
ST   Penta E: 7
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 18,20
DI   NCIt; C9280; Primary mediastinal (thymic) large B-cell lymphoma
DI   ORDO; Orphanet_98838; Primary mediastinal large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_QY35 ! Karpas-1106A
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=7949096; DOI=10.1182/blood.V84.10.3422.3422;
RA   Nacheva E., Dyer M.J.S., Metivier C., Jadayel D.M., Stranks G.,
RA   Morilla R., Heward J.M., Holloway T., O'Connor S., Bevan P.C.,
RA   Larsen C.-J., Karpas A.;
RT   "B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex
RT   translocation involving 18q21.3 but lacking BCL2 rearrangement and
RT   expression.";
RL   Blood 84:3422-3428(1994).
//
RX   PubMed=9724100; DOI=10.1002/(SICI)1097-0215(19980925)78:1<100::AID-IJC16>3.0.CO;2-F;
RA   Tamura A., Akagi T., Nakazawa N., Kashima K., Nakamura S., Karpas A.,
RA   Silverman G.A., Morishima Y., Taniwaki M., Seto M.;
RT   "Delineation of the breakpoint at 18q21.1 in a cell line (Karpas1106)
RT   derived from mediastinal B-cell lymphoma by fluorescence in situ
RT   hybridization with multiple YAC clones.";
RL   Int. J. Cancer 78:100-105(1998).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//